Ayala Pharmaceuticals, Inc. (ADXS)
(Delayed Data from OTC)
$0.02 USD
0.00 (0.00%)
Updated Aug 30, 2024 10:16 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Ayala Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 5 | 3 | 25 | 42 | 25 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 0 | 1 | 2 | 3 |
Total Current Assets | 8 | 3 | 26 | 43 | 28 |
Net Property & Equipment | 1 | 1 | 0 | 0 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 8 | 0 | 0 | 3 | 3 |
Deposits & Other Assets | 0 | 2 | 0 | 0 | 0 |
Total Assets | 17 | 8 | 26 | 47 | 39 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 4 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 2 | 2 | 3 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12 | 1 | 0 | 5 | 0 |
Total Current Liabilities | 25 | 8 | 2 | 8 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 8 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 8 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 41 | 9 | 2 | 8 | 8 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 173 | 148 | 467 | 467 | 441 |
Retained Earnings | -197 | -149 | -443 | -429 | -411 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -24 | -1 | 24 | 39 | 30 |
Total Liabilities & Shareholder's Equity | 17 | 8 | 26 | 47 | 39 |
Total Common Equity | -24 | -1 | 24 | 39 | 30 |
Shares Outstanding | 11.80 | 1.80 | 1.80 | 1.40 | 0.70 |
Book Value Per Share | -2.07 | -0.61 | 13.13 | 27.78 | 43.11 |
Fiscal Year End for Ayala Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 5 | 2 | 7 |
Receivables | NA | NA | 0 | 0 | 0 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 0 |
Other Current Assets | NA | NA | 3 | 2 | 2 |
Total Current Assets | NA | NA | 8 | 5 | 10 |
Net Property & Equipment | NA | NA | 1 | 1 | 1 |
Investments & Advances | NA | NA | 0 | 0 | 0 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | NA | 8 | 0 | 0 |
Deposits & Other Assets | NA | NA | 0 | 0 | 0 |
Total Assets | NA | NA | 17 | 7 | 12 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | NA | 6 | 5 | 4 |
Current Portion Long-Term Debt | NA | NA | 0 | 0 | 0 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | NA | 6 | 3 | 3 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | NA | 12 | 0 | 0 |
Total Current Liabilities | NA | NA | 25 | 9 | 8 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 8 | 2 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 8 | 2 | 2 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | NA | 41 | 13 | 11 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | NA | 0 | 0 | 0 |
Capital Surplus | NA | NA | 173 | 166 | 166 |
Retained Earnings | NA | NA | -197 | -173 | -165 |
Other Equity | NA | NA | 0 | 0 | 0 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | NA | -24 | -6 | 1 |
Total Liabilities & Shareholder's Equity | NA | NA | 17 | 7 | 12 |
Total Common Equity | 0 | 0 | -24 | -6 | 1 |
Shares Outstanding | 42.60 | 42.60 | 11.80 | 4.70 | 4.70 |
Book Value Per Share | 0.00 | 0.00 | -2.07 | -1.33 | 0.21 |